共同药业
(300966)
| 流通市值：11.25亿 | | | 总市值：18.10亿 |
| 流通股本：7167.47万 | | | 总股本：1.15亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 385,037,986.62 | 267,821,256.77 | 119,423,435.11 | 604,571,473.19 |
| 营业收入 | 385,037,986.62 | 267,821,256.77 | 119,423,435.11 | 604,571,473.19 |
| 二、营业总成本 | 372,954,404.95 | 257,381,345.37 | 120,171,920.93 | 566,088,639.79 |
| 营业成本 | 296,358,203.1 | 208,074,410.71 | 95,381,546.46 | 466,351,809.91 |
| 税金及附加 | 767,812.69 | 545,112.23 | 360,306.09 | 688,311.56 |
| 销售费用 | 3,651,441.69 | 2,424,285.01 | 868,263.18 | 4,907,013.77 |
| 管理费用 | 34,821,325.47 | 20,983,345.22 | 10,148,217.1 | 38,832,680.38 |
| 研发费用 | 30,315,565.77 | 21,036,108.58 | 10,545,515.62 | 45,147,487.65 |
| 财务费用 | 7,040,056.23 | 4,318,083.62 | 2,868,072.48 | 10,161,336.52 |
| 其中:利息费用 | 9,997,791.12 | 7,098,710.94 | 3,824,755.05 | 13,372,459.02 |
| 其中:利息收入 | 1,952,184.98 | 1,587,644.53 | 911,688.82 | 1,923,107.35 |
| 加:公允价值变动收益 | -11,877.68 | -11,877.68 | -8,240.96 | 11,877.68 |
| 加:投资收益 | -67,224.74 | 33,345.56 | 92,910.39 | -194,545 |
| 资产处置收益 | 168,297.3 | - | - | -6,259.82 |
| 资产减值损失(新) | -458,723.73 | -458,723.73 | - | 827,118.05 |
| 信用减值损失(新) | -731,085.8 | -919,626.55 | -568,938.26 | -4,503,310.84 |
| 其他收益 | 4,102,504.02 | 1,911,236.83 | 243,775.96 | 4,285,817.71 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 15,085,471.04 | 10,994,265.83 | -988,978.69 | 38,903,531.18 |
| 加:营业外收入 | 3,477,507.62 | 3,380,192.96 | 4,364,730.97 | 944,291.08 |
| 减:营业外支出 | 2,305.01 | 99.23 | 55.64 | 1,334,123.23 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 18,560,673.65 | 14,374,359.56 | 3,375,696.64 | 38,513,699.03 |
| 减:所得税费用 | -2,815,961.3 | -2,257,741.09 | -275,437.65 | -982,330.79 |
| 六、净利润 | 21,376,634.95 | 16,632,100.65 | 3,651,134.29 | 39,496,029.82 |
| 持续经营净利润 | 21,376,634.95 | 16,632,100.65 | 3,651,134.29 | 39,496,029.82 |
| 归属于母公司股东的净利润 | 22,784,477.65 | 17,472,034.33 | 4,024,418.08 | 40,187,745.43 |
| 少数股东损益 | -1,407,842.7 | -839,933.68 | -373,283.79 | -691,715.61 |
| (一)基本每股收益 | 0.2 | 0.15 | 0.03 | 0.35 |
| (二)稀释每股收益 | 0.2 | 0.15 | 0.03 | 0.35 |
| 九、综合收益总额 | 21,376,634.95 | 16,632,100.65 | 3,651,134.29 | 39,496,029.82 |
| 归属于母公司股东的综合收益总额 | 22,784,477.65 | 17,472,034.33 | 4,024,418.08 | 40,187,745.43 |
| 归属于少数股东的综合收益总额 | -1,407,842.7 | -839,933.68 | -373,283.79 | -691,715.61 |
| 公告日期 | 2023-10-25 | 2023-08-29 | 2023-04-25 | 2023-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |